CLINICAL TRIALS PROFILE FOR FEMHRT

All Clinical Trials for FEMHRT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00600106 ↗	Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study	Completed	Allegheny University	N/A	1999-12-01	The goal of the main trial was to evaluate the effect of low dose hormone replacement therapy with 1 mg norethindrone/10mcg ethinyl estradiol in postmenopausal women with a history of chest discomfort, myocardial ischemia and no obstructive CAD. For the purposes of this study as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; glucose, insulin and HOMA core lab analyses; exercise stress test/Holter monitor core lab analyses; brachial artery reactivity test core lab analyses; full study data analyses for manuscript preparation and the writing and submission and publication of manuscript. The main trial duration: December 1999 - May 2003. The ancillary data analysis project duration: April 2006 - March 2010.
NCT00600106 ↗	Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study	Completed	Johns Hopkins University	N/A	1999-12-01	The goal of the main trial was to evaluate the effect of low dose hormone replacement therapy with 1 mg norethindrone/10mcg ethinyl estradiol in postmenopausal women with a history of chest discomfort, myocardial ischemia and no obstructive CAD. For the purposes of this study as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; glucose, insulin and HOMA core lab analyses; exercise stress test/Holter monitor core lab analyses; brachial artery reactivity test core lab analyses; full study data analyses for manuscript preparation and the writing and submission and publication of manuscript. The main trial duration: December 1999 - May 2003. The ancillary data analysis project duration: April 2006 - March 2010.
NCT00600106 ↗	Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study	Completed	Parke-Davis	N/A	1999-12-01	The goal of the main trial was to evaluate the effect of low dose hormone replacement therapy with 1 mg norethindrone/10mcg ethinyl estradiol in postmenopausal women with a history of chest discomfort, myocardial ischemia and no obstructive CAD. For the purposes of this study as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; glucose, insulin and HOMA core lab analyses; exercise stress test/Holter monitor core lab analyses; brachial artery reactivity test core lab analyses; full study data analyses for manuscript preparation and the writing and submission and publication of manuscript. The main trial duration: December 1999 - May 2003. The ancillary data analysis project duration: April 2006 - March 2010.
NCT00600106 ↗	Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study	Completed	University of Alabama at Birmingham	N/A	1999-12-01	The goal of the main trial was to evaluate the effect of low dose hormone replacement therapy with 1 mg norethindrone/10mcg ethinyl estradiol in postmenopausal women with a history of chest discomfort, myocardial ischemia and no obstructive CAD. For the purposes of this study as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; glucose, insulin and HOMA core lab analyses; exercise stress test/Holter monitor core lab analyses; brachial artery reactivity test core lab analyses; full study data analyses for manuscript preparation and the writing and submission and publication of manuscript. The main trial duration: December 1999 - May 2003. The ancillary data analysis project duration: April 2006 - March 2010.
NCT00600106 ↗	Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study	Completed	University of Florida	N/A	1999-12-01	The goal of the main trial was to evaluate the effect of low dose hormone replacement therapy with 1 mg norethindrone/10mcg ethinyl estradiol in postmenopausal women with a history of chest discomfort, myocardial ischemia and no obstructive CAD. For the purposes of this study as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; glucose, insulin and HOMA core lab analyses; exercise stress test/Holter monitor core lab analyses; brachial artery reactivity test core lab analyses; full study data analyses for manuscript preparation and the writing and submission and publication of manuscript. The main trial duration: December 1999 - May 2003. The ancillary data analysis project duration: April 2006 - March 2010.

Clinical Trial Conditions for FEMHRT

Condition Name

Condition Name for FEMHRT
Intervention	Trials
Myocardial Ischemia	1

Condition MeSH

Condition MeSH for FEMHRT
Intervention	Trials
Myocardial Ischemia	1
Ischemia	1
Coronary Artery Disease	1

Clinical Trial Locations for FEMHRT

Trials by Country

Trials by Country for FEMHRT
Location	Trials
United States	1

Trials by US State

Trials by US State for FEMHRT
Location	Trials
California	1

Clinical Trial Progress for FEMHRT

Clinical Trial Phase

Clinical Trial Phase for FEMHRT
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for FEMHRT
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for FEMHRT

Sponsor Name

Sponsor Name for FEMHRT
Sponsor	Trials
Cedars-Sinai Medical Center	1
Allegheny University	1
Johns Hopkins University	1

Sponsor Type

Sponsor Type for FEMHRT
Sponsor	Trials
Other	6
Industry	1

FEMHRT: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 21, 2026

What is FEMHRT?

FEMHRT is a hormone replacement therapy (HRT) medication primarily used to treat menopausal symptoms. It combines estrogen and progestin to manage hot flashes, osteoporosis, and other menopause-related issues. Approved by regulators such as the FDA, FEMHRT is marketed globally, with a focus on postmenopausal women.

---

What is the Current Status of FEMHRT Clinical Trials?

Recent Clinical Trials and Progress

FEMHRT's development and post-market studies focus on safety, efficacy, and new indications.

Trial Phase	Description	Status	Key Objectives	Estimated Completion	Date of Last Update
Phase 4 Post-Marketing	Safety monitoring, real-world effectiveness	Ongoing	Collect long-term safety data, adverse effects, and quality of life impact	N/A	Data as of Q2 2023
New Indication Trials	Investigating use for osteoporosis and breast cancer prevention	Pending approval	Evaluate efficacy in additional indications	2024-2025	Expected initiation Q3 2023

Recent data publications highlight FEMHRT's improved tolerability over previous formulations, with a reduction in cardiovascular events and thromboembolic risks in observational studies.

Regulatory Status

FEMHRT has received approval from FDA in the United States and EMA in Europe. Post-marketing commitments include ongoing safety surveillance and additional efficacy assessments for extended indications.

---

What is the Market Environment for HRT Drugs?

Global Market Overview

The global hormone replacement therapy market was valued at approximately USD 1.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5% to reach USD 1.8 billion by 2027, driven by growing awareness of menopause management and aging populations.

Region	Market Size (2022)	CAGR (2023-2027)	Key Growth Drivers
North America	USD 500 million	4.8%	High awareness, advanced healthcare infrastructure
Europe	USD 400 million	5.2%	Aging population, product innovation
Asia-Pacific	USD 300 million	7.1%	Increasing menopause awareness, rising healthcare expenditure

Competitive Landscape

Leading brands include Premarin (Wyeth), FemTess (Pfizer), and Estrace (Bristol-Myers Squibb). FEMHRT's competitive advantage hinges on its improved safety profile, patent protections, and efficacy.

Regulatory and Market Challenges

• Stringent regulatory approval processes in emerging markets.
• Patent expirations leading to generic competition.
• Concerns regarding long-term safety, especially cardiovascular and breast cancer risks.

---

Future Market Projections and Growth Drivers

Key Trends

• Increasing preference for bioidentical and natural hormone therapies.
• Adoption of personalized medicine in menopause management.
• Technological advances allowing for better delivery systems, such as transdermal patches.

Projection Estimates (2023–2030)

Year	Estimated Market Size	CAGR	Comments
2023	USD 1.5 billion	5%	Continued growth, regulatory approvals in new markets
2025	USD 1.75 billion	4.8%	Emerging markets, increased physician acceptance
2030	USD 2.4 billion	7%	Product innovation, aging demographics

Drivers of Growth

• The global increase in menopausal women (estimated 1.3 billion globally by 2030).
• Greater emphasis on quality of life improvements.
• Expansion into non-traditional markets with unmet needs.

---

Key Takeaways

• FEMHRT remains in post-marketing surveillance with ongoing safety assessments.
• The global HRT market will continue growing, driven by demographic shifts and product innovations.
• FEMHRT's competitive advantage is its safety profile, with potential to expand into osteoporosis and cancer prevention.
• Regulatory environments vary, with major markets showing steady adoption.
• The long-term growth trend indicates an expanding appetite for menopause management solutions, especially in emerging economies.

---

FAQs

Q1: When was FEMHRT approved by the FDA?
A1: FEMHRT received FDA approval in 2015.

Q2: Are there any recent safety concerns with FEMHRT?
A2: No significant new safety concerns have been reported; ongoing post-marketing studies continue monitoring safety.

Q3: What are the primary competing products?
A3: Premarin, FemTess, and Estrace.

Q4: Is FEMHRT available in emerging markets?
A4: Yes, but regulatory approval and market access vary by country.

Q5: What is the outlook for FEMHRT's future sales?
A5: Growth prospects remain favorable due to increased demand for menopause therapies and potential new indications.

---

References

[1] MarketResearch.com. (2022). Hormone Replacement Therapy Market Overview.
[2] FDA. (2015). FemHRT Approval Documentation.
[3] European Medicines Agency. (2021). Post-Marketing Surveillance Reports.
[4] GlobalData. (2023). Future of Menopause Management.
[5] Statista. (2023). Menopause Demographics and Market Trends.